INTRODUCTION
Chronic infection with the hepatitis C virus (HCV) can lead to the generally asymptomatic phase of compensated cirrhosis, from which progression to the severe, life-threatening stage of decompensated cirrhosis (DC) occurs with a 10-year cumulative incidence of 42%. 1 In the predirect acting antiviral (DAA) therapy era, the annual risk of mortality following DC without liver transplantation was very high. 2 A recent Scottish record-linkage study reported a 5-year cumulative risk of mortality of 70% after first inpatient hospital admission for DC, with no evidence for any improvement in mortality risk over the 20-year study period 1994-2013. 3 Upon expansion of DAA treatment to DC-stage patients, 4 promising reported viral clearance rates 5,6 may translate to improved survival, but data from long-term follow-up studies are not yet available.
Mortality findings may not generalise to temporal trends in the morbidity burden. Because of -in some cases, extensive -co-morbidities among HCV-infected persons (for instance, mental health disorders, 7 or conditions related to lifestyle behaviours such as problem alcohol/drug use; 8 or chronic diseases prevalent in older persons: cardiovascular and respiratory impairments; diabetes, cancer; e.g., Ref. 9) , it is important to quantify the health-care associated burden in this patient population attributable to both liver-and non-liver related causes.
The financial burden due to patient care and management once chronic HCV patients progress to the DC stage is recognised as considerable. For instance, economic evaluations carried out for the USA birth cohort screening initiative adopted annualised direct costs for DC patient care in the range of US$11,000 to $28,000. [10] [11] [12] In the European setting, annual hospitalisation costs of 8000-20,000 euros for DC patients have been estimated for France 13 and 28,000 euros for the Netherlands. 14 In one of the few UK studies to quantify the length of hospital stay in HCV-infected patients according to disease stage, 15 21 .1 days was reported as the mean annualised length of stay in hospital for DC patients (without HCC), with 22.6 days per year for HCC patients (with or without DC). The authors translate these figures to a mean annual total cost of £9,120 per year (in 2002/03 prices), of which the principal cost component was inpatient hospital stay, accounting for more than 70% of the total cost. These values are based on 40 DC and 20 HCC patients taking part in an observational costing substudy of the UK Mild Hepatitis C trial, 15, 16 and the associated costeffectiveness analysis for the National Institute for Health and Care Excellence depended on these burden estimates. Although estimates from the MILD trial are derived from a small study population over a two-year recruitment period more than 15 years ago, subsequent economic analyses both in and outwith the UK still use these figures (e.g., Refs. 17, 18) . It is therefore prudent to derive updated estimates using a larger, national sample of patients, and to consider the excess hospitalisation that may not be directly related to HCV liver disease, but nonetheless occurs in these patients. Updated hospital stay data will also serve a vital role for assessing the impact of interferon-free antiviral therapy in preventing DC and its associated morbidity.
The current study follows-up a large nationwide cohort of patients admitted to hospital with DC, to generate real-world estimates of morbidity burden in this population. Our primary goal was to quantify the extent of inpatient hospital usage among DC patients by calculating the mean cumulative length of stay for all admissions and for liver-related and non-liver related admission categories separately. As secondary objectives we analysed temporal trends in admission rates, and investigated the distribution of admissions according to severity over the follow-up period.
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MATERIALS AND METHODS
Data sources and record-linkage
Linkage of three national data sources was carried out by Information Services Division (a division of NHS National Services Scotland) using probabilistic record-linkage techniques. 19 This linked dataset was anonymized prior to transfer to HPS for analysis. Data linkages were approved by the Privacy Advisory Committee, which oversees confidentiality issues involving data held on NHS Scotland patients. Further ethical approval and informed consent were not required for this database study.
The linked dataset consisted of: (i) a database, maintained by Health Protection Scotland, of all persons in Scotland who have been diagnosed HCV positive since testing commenced in 1991 (including stored serum back to 1985); 20 laboratory detection of hepatitis C antibody is an inclusion criterion. As of 31 December 2013, the HCV Diagnosis database contained records for 35,474 persons. 21 It is estimated that approximately 55% of the current HCV-infected Scottish population have been diagnosed. 22 A further linkage between the HCV Diagnosis and the Scottish Hepatitis C Clinical Database was conducted at HPS to determine the HCV RNA status at date of index DC admission for those patients who had previously been successfully treated with antiviral therapy (see Ref. 23 for further details). This database, also held at Health Protection Scotland, contains data on all aspects of HCV care and patient management and is deployed at specialist HCV treatment centres within Scotland.
Study population
The study population consisted of all HCV-diagnosed patients with a first inpatient/day-case admission for DC in Scotland over the period 1996-2013. Patients whose first DC admission occurred more than one year preceding HCV diagnosis were excluded, in an attempt to reduce potential bias due to DC arising from a different aetiology. HCV RNA status was not restricted to PCR-positive in the principal analysis, but in sensitivity analyses we stratify by RNA status.
An admission for DC was defined according to the presence of a relevant ICD-10 code(s) in either the main or five supplementary diagnosis fields of the episode record. DC discharge diagnosis codes were categorised into: hepatic failure (aggregating the diagnosis codes comprising chronic hepatic failure, alcoholic hepatic failure, and hepatorenal syndrome), ascites, and bleeding oesophageal varices (for ICD-10 codes comprising these definitions see Supporting Information, Table S1 ). The selected diagnosis codes have been used in previous DC research. 3, 24 We use the terms admission and discharge equivalently, assuming that discharge diagnoses encode the reason for admission. Successive inpatient episodes without release from hospital, and/or transfers between specialty or consultant, with identical sets of discharge diagnoses, are counted as a single admission. Episodes with an identical date of admission and discharge (most often day-cases) contributed 0.5 days to measures of total hospital stay. Outcome measures. From the DC patients´ entire hospital record including and subsequent to the first DC admission, the total number of inpatient admissions, admission rate, and total stay in hospital were calculated for each year of the study period, and the mean cumulative stay per patient was calculated according to various follow-up definitions (see below). We report all-cause admissions (i.e., with any diagnosis), and distinguish liver-related and non-liver-related admissions: (a) liver-related, consisting of: HCC, hepatic failure (chronic liver failure, hepatorenal syndrome), ascites/bleeding varices, other liver-related admissions (which includes alcohol-related diagnosis codes; see Table S1 ); (b) non-liver related admissions -these consisted of all other admissions in which none of the above codes were indicated in any of the five discharge diagnosis fields. The subcategories of liver-related admissions were defined hierarchically according to severity (itself defined according to short-term mortality risk); i.e., if an HCC code occurred in any diagnosis field, then the episode was categorised as HCC. However, if no HCC code, but a hepatic failure code occurred in any diagnosis field, then the episode was classified as hepatic failure.
Patient characteristics and exposure variables
Classification of episodes into categories lower in the hierarchy was conducted analogously; i.e., if no liver-related code occurred in any diagnosis field, the episode was classified as a non-liver related admission.
Within the category 'non-liver related', four subcategories were defined based on frequency of occurrence: circulatory and respiratory, digestive system other than liver, injuries and poisonings, and other non-liver (Supporting Information, Table S1 ). Each non-liver related episode was classified using an analogous hierarchical procedure. In the second follow-up definition, in which admission rate across triennium of the study period is investigated (Table 1b) Sensitivity analyses. We conducted comparable analyses to those described earlier, but restricted the study population to HCV RNA-positive persons, and also compared mean cumulative length of stay across HCV RNA status categories (see Supporting Information, Tables S2 and S3 ).
Statistical analyses.
Multifactorial Poisson regression was used to infer the patient and other factors (age, sex, RNA status, admission for HCC prior to first DC admission, period of first DC admission) associated with cumulative length of hospital stay. We define cumulative length of stay as the total stay in hospital (i.e., summing multiple admissions) within a patient's follow-up period.
We used Cox regression with robust standard errors to confirm temporal trends in admission rates for all admissions, and in admission rates categorised as liver-related only, controlling for important confounders (age, sex, risk group, prior alcohol-related admission, HCV RNA status, and prior HCC admission).
The counting-process formulation for recurrent events was adopted for person-time analyses. All statistical analyses were conducted using R statistical computing software. 25 
RESULTS
Patient characteristics
A total of 1,543 HCV diagnosed persons had a first inpatient hospital admission for DC within the period 1996-2013, increasing 3.9-fold between 1996-98 and 2011-13 (Table 1a) . Males constituted the majority of patients (73%), and the mean age at first DC admission was 47 years. Previous to their first DC admission, 56% and 4.2% had an alcohol-related admission or HCC admission, respectively. Seventy-seven percent of patients had tested HCV RNA-positive prior to index admission (85% of those whose HCV RNA status was known). As of 31 May 2014, 457 (30%) DC patients were not known to have died.
The most prevalent DC diagnosis code at index DC admission, over all six triennia, was ascites (57%), followed by chronic hepatic failure (21%). The prevalence of both ascites and alcoholic hepatic failure tend to increase with triennium, whereas the prevalence of bleeding varices tend to decrease over the study period.
Temporal trends in inpatient admissions and total stay
Between 1996 and 2013, the total number of inpatient admissions among the study population of HCV diagnosed patients with DC increased 16-fold, from 112 to 1791, and the annual total inpatient hospital stay also increased 11-fold over the same period, from 719 days in 1996 to 8045 in 2013 ( Fig. 1 Aggregating over all six triennia, there were 10,179 inpatient admissions in total, for an overall admission rate of 7.9 admissions per person-year (Table 1b) Table S4 ). The median length of stay per admission was constant at 3 days from the beginning of the study period, dropping to 2 days in the most recent triennium.
In sensitivity analysis of the study population restricted to chronically-infected (HCV RNApositive) individuals, very similar temporal trends in admission rates were apparent (Supporting Information, Table S3 ). (Table 3 ). Patients aged 60+ years had longer total stay (RR=1.11, 95% CI: 1.08-1.14), as did patients with one or more alcohol-related admissions before first DC admission (RR=1.21, 95% CI: 1.19-1.23), but having ever been admitted for HCC prior to first DC admission (RR=0.68, 95% CI: 0.64-0.71) or if first DC admission was for bleeding varices (RR=0.83, 95% CI: 0.80-0.85) was associated with a shorter stay. Table S5 ).
Length of stay since first DC admission
In sensitivity analysis comparing RNA-positive and RNA-negative subgroups, there was little difference in cumulative stay per patient considering admissions for any reason, except that RNAnegative patients had a slightly higher average cumulative stay for the category other liver-related compared with RNA-positive DC patients (15.5 and 13.8 days, respectively; Table S2 ). Among the subcategories of non-liver related admissions, there was no observable pattern by year of follow-up (Fig. S3a) , but the proportion of admissions classified as injuries and poisonings was highest for the youngest age-group, and the proportion of admissions in the category circulatory and respiratory tended to increase with older age-group (Fig. S3b) .
Proportion of admissions with liver -and non-liver related diagnoses
DISCUSSION
The burden of hospital usage in our DC patient population is high; our DC patients spent on average 43 days in hospital (Table 2) , assuming a follow-up period censored at 2 years following index DC admission. The inpatient hospital burden is greatest within the year immediately after admission for the first decompensation event, and diminishes thereafter (Fig. S1 , Table S5 ). We Our estimates of the per-patient mean hospital stay varied by period of follow-up (Table S5) We observed an approximate monotonic increase in annual total hospital stay over the study period, consistent with a rapid rise in the cumulative number of living DC patients over the period 1994-2013. 3 The decreasing trend in mean stay for admissions for HCC or DC over the study period may indicate improved management of patients with the most severe disease, but also could reflect changing practice in outpatient vs. inpatient treatment, but we have no data to address this. The apparent decreasing trend across triennium in the prevalence of bleeding varices at first DC admission (Table 1 ) may be a consequence of earlier detection via screening initiatives and consequent treatment (P. Hayes, pers. comm.)
We note that focussing on DC/HCC admissions only does not reflect the extensive hospital burden borne by this patient group. Although admissions for hepatic failure and ascites/varices led to a mean cumulative inpatient stay of 11 and 13 days, respectively (Table 2) , the mean cumulative length of stay for liver-related diagnoses outwith the defined DC codeset was comparable, at 14 days. The other liver-related subcategory includes 'Alcoholic liver disease, unspecified' (K70.9) -the most frequently occurring code in this subcategory -suggesting that the high prevalence of current or historical problem alcohol use in this DC patient population contributes a significant portion of the hospitalisation burden. Furthermore, separation of RNA-positive and RNA-negative patients indicated that average cumulative stay with respect to the other liver-related category was approximately 12% longer for the latter subgroup (Table S2 ). This difference is consistent with a higher likelihood that progression to DC in the RNA-negative subgroup was driven more by alcohol then HCV infection.
Limitations of our study include possible misclassification error in the coding of hospital admissions. We also lacked information on clinical disease stage or on liver transplantation. The apparent greatly improved disease course in a proportion of our DC patients (as indicated by no further inpatient admissions after an initial cluster of DC and other liver-related admissions) could indicate reversal of severe disease, potentially via successful transplantation. However, relatively few liver transplantations took place during the study period, and transplant patients in Scotland can have an inpatient record generated with a code indicating prior liver transplantation; this occurred for only a small proportion. 3 We considered the first 2 years following first DC admission to usefully represent the typical DC patient's inpatient history. All censoring thresholds are arbitrary, but for estimation of the burden of hospital usage in DC patients, using this threshold to interpret the results represents an arguably reasonable compromise between capturing the excess morbidity in this population and discounting ´background morbidity´.
In summary, we report a substantial rising burden of inpatient hospital usage among Scottish HCV-diagnosed patients with decompensated liver disease. The average length of hospital stay was clearly dependent on follow-up period, with the highest burden observed in the initial year after developing DC. During our study period there were very few DC patients who would have been initiated on direct-acting antiviral (DAA) treatment; this study should be repeated once sufficient follow-up is available for the expected increasing numbers of patients who will clear the virus following DAA treatment. Nevertheless, the present findings will be eminently useful for evaluations of the impact of interferon-free antiviral therapy in preventing DC and associated morbidity (as indicated by inpatient hospital stay), and in potentially reducing liver and non-liver related morbidity among successfully treated DC patients, for whom current guidelines recommend urgent treatment. 26 
